Evidence map›Paper›PMID 42062516›Full record

ArticleNature structural & molecular biology2026

Hypervariable loop profiling decodes sequence determinants of antibody stability.

Yue Wan, Jiahao Liang, Yile Dai, Karthik Srinivasan, Christian Billesbølle, Ju-Fen Zhu, Jung-Eun Shin, Steffanie Paul, Debora Marks, Yun S Song and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature structural & molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yue WanDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Jiahao LiangDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Yile DaiDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Karthik SrinivasanDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
Christian BillesbølleDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.ORCID http://orcid.org/0000-0001-8084-1552
Ju-Fen ZhuDepartment of Oncological Sciences, Department of Biochemistry, Department of Bioengineering, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Jung-Eun ShinDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.
Steffanie PaulDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.
Debora MarksDepartment of Systems Biology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9388-2281
Yun S SongDepartment of Electrical Engineering and Computer Sciences, University of California, Berkeley, Berkeley, CA, USA.ORCID http://orcid.org/0000-0002-0734-9868
Benjamin R MyersDepartment of Oncological Sciences, Department of Biochemistry, Department of Bioengineering, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID http://orcid.org/0000-0003-0975-539X
Antoine KoehlDepartment of Electrical Engineering and Computer Sciences, University of California, Berkeley, Berkeley, CA, USA. antoinekoehl@gmail.com.ORCID http://orcid.org/0000-0003-2367-1096
Aashish ManglikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA. Aashish.Manglik@ucsf.edu.ORCID http://orcid.org/0000-0002-7173-3741

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody folding and aggregation are major challenges in the development of relevant reagents and therapeutics. Antibodies face a biophysical trade-off; the immense diversity in complementarity-determining regions (CDRs), which is crucial for broad antigen recognition, comes at the cost of folding stability. How CDR sequences influence antibody folding remains poorly understood because of their sequence diversity and lack of large-scale data. Here we develop a high-throughput 'deep loop profiling' approach to quantify folding fitness across millions of diverse CDRs. Machine learning models trained on this dataset predict folding propensity directly from sequence and identify interpretable residue-level rules that reveal CDR1 and CDR2 as key folding determinants. Using these insights, we rescue two unstable nanobodies, including an aggregation-prone SARS-CoV-2 binder and a G-protein-coupled receptor-targeting intrabody, and build next-generation synthetic libraries enriched for biophysically optimized nanobodies. This approach provides a scalable framework for understanding and engineering folding competence in antibody-based scaffolds.

Indexed as

Complementarity Determining RegionsSingle-Domain AntibodiesAmino Acid SequenceHumansMachine LearningModels, MolecularProtein FoldingProtein StabilitySARS-CoV-2Complementarity Determining RegionsSingle-Domain Antibodies

Identifiers

PMID42062516

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.